Stock ticker :
NYSE
JNJ
AS OF
Jan 14, closing price
Price
$167.80
Change
-$0.99 (-0.59%)
Capitalization
$441.9b
JNJ
Stock ticker :
NYSE
7 days until earnings call
Intraday data for
Jan 14, closing price
Price
$167.80
Change
-$0.99 (-0.59%)
Capitalization
$441.9b

(JNJ) Stock Forecast and AI Recommendations

an investment holding company with interests in health care products
Industry PharmaceuticalsMajor

Johnson & Johnson (JNJ) Stock Stock Prediciton and Price Targets

Stock market charts, price targets, analyst ratings and a financial calendar
an investment holding company with interests in health care products
Industry PharmaceuticalsMajor
A.I.dvisor published
a Summary for JNJ with price predictions.
4:00 PM EST Jan 14

JNJ in upward trend: price may jump up because it broke its lower Bollinger Band on January 14, 2022

JNJ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 22 of 32 cases where JNJ's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 69%.

Stock Forecast, Price, News, Quote

Current price $167.80 crossed the resistance line at $165.15 and is trading between $194.38 resistance and $165.15 resistance lines. Throughout the month of 12/14/21 - 01/14/22, the price experienced a -1% Downtrend. During the week of 01/07/22 - 01/14/22, the stock fell -4%.

Technical Analysis (Indicators)
Bullish Trend Analysis

The Stochastic Indicator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The 10-day Moving Average for JNJ crossed bullishly above the 50-day moving average on December 13, 2021. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 56%.

Following a +1.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 154 of 337 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.

The Aroon Indicator entered an Uptrend today. In 125 of 303 cases where JNJ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 41%.

Bearish Trend Analysis

The 10-day RSI Indicator for JNJ moved out of overbought territory on December 17, 2021. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In 21 of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at 48%.

The Momentum Indicator moved below the 0 level on January 12, 2022. You may want to consider selling the stock, shorting the stock, or exploring put options on JNJ as a result. In 25 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 33%.

The Moving Average Convergence Divergence Histogram (MACD) for JNJ turned negative on January 11, 2022. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 17 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 37%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 30%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.289) is normal, around the industry mean (5.061). P/E Ratio (25.063) is within average values for comparable stocks, (30.303). Projected Growth (PEG Ratio) (1.625) is also within normal values, averaging (2.433). Dividend Yield (0.025) settles around the average of (0.025) among similar stocks. P/S Ratio (4.907) is also within normal values, averaging (4.595).

The Tickeron Profit vs. Risk Rating rating for this company is 18 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating steady price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 66 (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.dvisor published
Johnson & Johnson Earnings Data

JNJ is expected to report earnings to fall 17.31% to $2.15 per share on January 25

Johnson & Johnson JNJ Stock Earnings Report
Q4'21
Est.
$2.15
Q3'21
Beat
by $0.25
Q2'21
Beat
by $0.19
Q1'21
Beat
by $0.25
Q4'20
Beat
by $0.04
The last earnings report on October 19 showed earnings per share of $2.60, beating the estimate of $2.35. With 5.83M shares outstanding, the current market capitalization sits at 441.86B.
A.I.dvisor found
Johnson & Johnson Dividends
JNJ paid dividends on December 07, 2021
Johnson & Johnson JNJ Stock Dividends
А dividend of $1.06 per share was paid with a record date of December 07, 2021, and an ex-dividend date of November 22, 2021. The ex-dividend date is usually set several business days before the record date. If a stock is purchased on its ex-dividend date or after, the next dividend payment will not be received. Instead, the dividends are repossessed by to the seller. If the stocks are purchased before the ex-dividend date, the buyer will receive the dividends.
A.I.dvisor
published General Information

General Information

Profile
Fundamentals
Details
Industry Pharmaceuticals Major
Address One Johnson and Johnson Plaza, New Brunswick, NJ, 08933
Phone +1 732 524-0400
Employees 134500
Web http://www.jnj.com
JNJ

Select Stock attributes to show

Capitalization 442B
P/E Ratio 25.06
Risk (Beta) 0.73
Dividend Yield 0.03
Total Cash 31B
Total Cash/Share 11.78
Total Debt 33.9B
Total Debt/Equity 22.58
Projected Growth (PEG Ratio) 1.63
Revenue/Share (as % of the share price) 34%
Revenue 91.4B
ROE N/A
Book Value 70.3B
P/B Ratio 6.29
Cash Flow N/A
Earnings 6.790
Average Daily Volume YTD N/A
Common Shares Outstanding - Security Level 3.12B
Current Ratio 1.34
Current Revenue Per Employee 171,099.70
Dividends Per Share - Security 1.06
EBITDA 27.3B
Float N/A
Float - Current N/A
Gross Income Margin 68.93
Revenue To Assets 10.22
Shares Held By Institutions 2.336T
Shares Outstanding - Current N/A
Total Liabilities 109B
Total Volume MTD N/A
Value Over
Gain YTD -1.888
Group Domestic Stock Funds
Category Pharmaceuticals
Total Expense Ratio
Min. Initial Investment 0.00 USD
Fund Existence
Turnover
Front Load
Net Assets 0.00 USD
Manager Tenure
Group Domestic Stock Funds
Category Pharmaceuticals
Capitalization 441.86b USD
P/E Ratio 25.062656
Total Cash 31.00b USD
Projected Growth 1.63
Total Debt 33.93b USD
Revenue 91.45b USD
Risk (Beta) 0.73
Dividend Yield 0.03
Total Cash/Share 11.78
Total Debt/Equity 22.58
Revenue/Share 34.00USD as % of share price
Group Domestic Stock Funds
Category Pharmaceuticals
Net Assets 0.00 USD
Fund Existence
Turnover
Capitalization
Yield
Total Expense Ratio
Investment Style
Risk (Beta)
Group Domestic Stock Funds
Category Pharmaceuticals
Market Capitalization 0.00 USD
Volume 0.00 USD